Rev Esp Quimioter 2017; 30(1):28-33

Epidemiology and risk factors of patients with intra-abdominal postsurgical infection treated with tigecycline: a cohort study                    

GLORIA TORRES, MIRIAM PAREDES, ALICIA HERNÁNDEZ, CRISTINA GARCÍA, FRANCISCO SÁNCHEZ BUENO, MANUEL CANTERAS, PASCUAL PARRILLA, JOAQUÍN GÓMEZ           

Objectives. To study a cohort of patients with intra-abdominal postsurgical infection treated with tigecycline to analyze its effectiveness and mortality related factors.
Patients and methods.  Prospective study of patients with intra-abdominal postsurgical infection with microbiological isolation and treated with tigecycline.
Results. Out of 103 patients only 61 full fit inclusion criteria. Mean age was 67 year-old and 72% were male. Charlson score was ≥ 3 in 65.5%, being diabetes and colon cancer the most prevalent diseases. Cancer surgery was the most frequent procedure (n=44, 72%) and previous antibiotic administration was present in 43 cases (69%). Pitt score was ≥ 3 in 69% and most prevalent bacteria were Escherichia coli (38 %), Enterococcus spp. (34%; mainly Enterococcus faecium) and Klebsiella pneumoniae together with Enterobacter cloacae (28%). Tigecycline was prescribed alone (17; 28%) or in combination with other antibiotics (44; 72%), mainly meropenem (25; 57%) or amikacin (19, 43%). 11 patients died (18%), all of which suffered extended cancer surgery and isolation of extended-spectrum betalactamase producing Enterobacteriaceae. Factors statistically associated to death in univariate analysis were Charlson score >3, pH <7.3 and leucocyte count >20.000 cells/mm3.
Conclusions. As being a cohort of patients treated with tigecycline, E. faecium isolation was very frequent. Non-fatal evolution was achieved in 82% cases, being tigecycline a potentially good option in the empiric treatment of very severe infections.

Rev Esp Quimioter 2017; 30(1):28-33 [pdf]

Rev Esp Quimioter 2017, Mar 31

Clinical presentation of candidaemia in elderly patients: experience in a single institution                     

ANA LERMA, ELENA CANTERO, MARÍA SORIANO, BEATRIZ ORDEN, ELENA MUÑEZ, ANTONIO RAMOS-MARTINEZ           

Objective. To analyse the clinical presentation of candidaemia in elderly patients.
Methods. A comparison of clinical presentation of candidaemia cases was carried out in a Spanish tertiary hospital between January 2010 and September 2015.
Results. Forty-five cases (32%) corresponded to elderly patients (≥ 75 years) and 95 cases (68%) to non-elderly patients (16-74 years). A higher proportion of elderly patients presented solid tumour (51% versus 32%, p=0.026) and a lower proportion had undergone solid or hematopoietic transplantation (0% versus 28%, p<0.001). Fewer elderly patients (16 patients, 36%) had a central venous line inserted than non-elderly patients (81 patients, 85%, p<0.001). Isolation of Candida parapsilosis was significantly lower among elderly (13.3%) than among non-elderly patients (32%, p=0.015). Fundoscopy was carried out in 20 elderly (44%) and in 64 younger patients (67%, p=0.009). The proportion of patients who underwent echocardiography was similar in both groups (56% vs 66%, respectively; p=0.218). Adequate antifungal treatment within the first 48 hours was administered in16 elderly patients (36%) and 58 younger patients (61%, p=0.005). Catheter removal was carried out in 9 elderly patients (68.1%) and in 40 non-elderly patients (49%, p=0.544). Mortality was higher among elderly patients (55.6%) than non-elderly patients (36.8%; p=0.037).
Conclusions. Elderly patients account for a substantial proportion of patients suffering from candidaemia in recent years. The clinical management of these patients was less appropriate than in younger patients with respect to fundus examination and the prescription of appropriate antifungal treatment. Mortality in elderly patients was higher than in younger patients.

Rev Esp Quimioter 2017; Mar 31 [pdf]

Rev Esp Quimioter 2015:28(2):92-97

Mortality among methicillin-resistant Staphylococcus aureus carriers in long-term care facilities                                  
 


ESTER VENDRELL, JOSEP A CAPDEVILA, PILAR BARRUFET, LLUÍS FORCE, GORETTI SAUCA, ENCARNA MARTÍNEZ, ELISABET PALOMERA, MATEU SERRA-PRAT, JORDI CORNUDELLA, ANNABEL LLOPIS, MªASUNCIÓN ROBLEDO, CRISÓSTOMO VÁZQUEZ      
        

 

Introduction. Little is known about the natural course of patients with chronic stable illnesses colonized with methicillin-resistant Staphylococcus aureus (MRSA). The aim is to determine the impact of MRSA colonization in mortality among long-term health care facility (LTHCF) residents.
Method. A multicenter, prospective, observational study was designed. Residents in 4 LTHCFs were classified according to MRSA carriage status and followed for 12 months. Treatment consisted of 5 days of nasal mupirocin in MRSA carriers.
Results. Ninety-three MRSA-carriers among 413 residents were identified. Thirty-one MRSA-colonized patients died during the study period, 11 of whom from an infectious disease. Independent predictors of their higher mortality rates included heart failure, current neoplasm, MRSA carriage and COPD at 3 months and these same factors plus stroke, Bar-thel index <40, pressure ulcers, and older age at 12 months. MRSA-persistence was 35% and 62.5% at 3 and 12 months, respectively.
Conclusions. MRSA colonization among frail LTHCFs residents is highly prevalent, and is associated with higher mortality. Despite treatment of MRSA carriers, many remained colonized. Factors that promote persistence of MRSA colonization, and the impact of their modification on mortality rates in these patients, need further investigation.

Rev Esp Quimioter 2015:28(2):92-97 [pdf]

Rev Esp Quimioter 2015:28(4):214-216

Could ceftaroline be an alternative therapy for linezolid resistant Staphylococcus epidermidis infections in Intensive Care Medicine?     

                        
FRANCISCO JAVIER CANDEL, ELVIRA BAOS, MERCEDES NIETO, JUAN JOSÉ PICAZO              

Introduction. Coagulase negative Staphylococcus continues generating interest in critically ill patients, due to their infections in extended admissions, in instrumented patients and due to their described multidrug resistance, which include glycopeptide heterorresistance and the increase in oxazolidinone resistance. Ceftaroline is a new cephalosporin with activity against resistant gram-positives, which, being betalactam, may provide adequate safety profile in the critical ill patient. The aim of this study was to determine the activity of ceftaroline and other antimicrobial agents against methicillin and linezolid-resistant Staphylococcus epidermidis.
Material and methods. We studied susceptibility of ceftaroline, tigecycline, daptomycin and vancomycin in a total of sixty-eight methicillin and linezolid-resistant S. epidermidis isolates with clinical significance from an Intensive Care Unit, using E-test.
Results. All strains were susceptible to the four antimicrobial agents, regardless of the level of resistance to linezolid.
Conclusion. Ceftaroline could be an alternative in the treatment of methicillin and linezolid-resistant S. epidermidis infections in critically ill patients.

Rev Esp Quimioter 2015:28(4):214-216 [pdf]

Rev Esp Quimioter 2015:28(5):235-241

Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting     

                        
NICOLÁS DI BENEDETTO, MARTA MONTERO-ALONSO, MARINO BLANES, JOSÉ LACRUZ, SANDRA CUELLAR, EVA CALABUIG, JOSÉ LÓPEZ, MIGUEL SALAVERT              

Background. Boosted protease inhibitor monotherapy may offer antiviral efficacy while reducing drug interactions, costs and toxicity. The aim of this study was to assess the efficacy of darunavir/ritonavir (DRV/r) and lopinavir/ritonavir (LPV/r) monotherapy in a real life setting.
Methods. A retrospective analysis of all HIV infected patients, who had initiated DRV/r or LPV/r monotherapy, was performed. Patients whose HIV viral load had remained undetectable for at least two consecutive follow-up visits and who had no neurocognitive disorder or hepatitis B co-infection, were included.
Results. Sixty patients were included. The median (IQR) time to follow-up was 66 (33-118) weeks. The proportions (CI95%) of patients with virological failure were 6.3% (1.7- 20.2) and 25.0% (12.7-43.4), respectively, in the DRV/r and LPV/r groups (p= 0.0424). The proportions (CI95%) of patients with therapeutic success were 90.6% (80.5-100) in the DRV/r group and 60.7% (42.6-78.8) in the LPV/r group (p=0.0063). No protease inhibitor mutations were detected. During the follow-up, 6 patients with dyslipidemia normalized their lipid values. The median monthly cost was 410 (IQR 242-416) euros per person lower for the monotherapy than for the combined antiretroviral therapy.
Conclusions. Boosted protease inhibitor monotherapy was effective in a real life setting. This study showed differences in favour of DRV/r as compared with LPV/r in terms of therapeutic success; however prospective studies are needed to confirm these results. Finally, although this study was not specifically designed to detect benefits in terms of costs and lipid profile, it shows evidence of a positive impact of monotherapy in these fields.

Rev Esp Quimioter 2015:28(5):235-241 [pdf]

Rev Esp Quimioter 2016,29(1):40-43

Adherence to international recommendations in the fight against antimicrobial resistance – Substantial difference between outpatient consumption in Spain and Denmark     

                        

SARA MALO, MARÍA JOSÉ RABANAQUE, LARS BJERRUM              

Introduction. Increasing antibiotic resistance represents a major public health threat that jeopardises the future treatment of bacterial infections. This study aims to describe the adherence to recommendations proposed by the World Health Organization (WHO) Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR), in Spain and Denmark, and to analyse the relation between the outpatient use of Critically Important Antimicrobials (CIA) and the bacterial resistance rates to these agents.
Material and methods. The Antimicrobial consumption interactive database (ESAC-Net) and Antimicrobial resistance interactive database (EARS-Net) provided data on outpatient use (2010-2013) of CIA (fluoroquinolones, macrolides, and 3rd and 4th generation cephalosporins) and the percentages of isolates of the main pathogens causing serious infections, resistant to these agents.
Results. The use of cephalosporins and fluoroquinolones, as well as the percentage of bacteria resistant, is higher in Spain than in Denmark. Although consumption of macrolides in both countries is similar, the proportion of Streptococcus pneumoniae resistant to macrolides is significantly higher in Spain.
Conclusion. The high outpatient consumption of CIA agents in Spain deviates substantially from the WHO recommendations. Moreover, it has the effect of elevated rates of antimicrobial resistance, that are lower in Denmark.

Rev Esp Quimioter 2016;29(1):40-43 [pdf]

Rev Esp Quimioter 2016, 29(4):175-182

How should we approach Aspergillus in lung secretions of patients with COPD?   

                    

JOSÉ BARBERÁN, FRANCISCO JAVIER CANDEL, ANA ARRIBI             

Aspergillus spp. is frequently isolated in respiratory samples from patients with severe COPD; however, the clinical significance of this mold is unclear and its presence may indicate temporary passage, benign chronic carriage, or onset of invasive disease. The definitive diagnosis of pulmonary aspergillosis in COPD patients is often difficult owing to the lack of specific clinical and radiological signs. However, retrospective studies show the risk for developing pulmonary aspergillosis in older patients with severe COPD, and a high number of comorbidities who have received treatment with corticosteroids and/or broad spectrum antibioties. The development of algorithms based on microbiological and radiological data and risk factors for pulmonary aspergillosis can help to differentiate between colonization and infection.

Rev Esp Quimioter 2016; 29(4):175-182 [pdf]

Rev Esp Quimioter 2016, 29(Suppl. 1):6-9

Epidemiology of the infection by resistant Gram-positive microorganisms                    

EMILIA CERCENADO          

Resistance among Gram-positive microorganisms to classical and new antimicrobials is a therapeutic threat. In Spain, methicillin resistance among Staphylococcus aureus (25-30%) and coagulase-negative staphylococci (50-60%) seems to have stabilized in the last decade. Among enterococci, vancomycin resistance is less than 5%. Both linezolid and daptomycin, in general, show good activity against these microorganisms. However, the resistance rates of Staphylococcus epidermidis to linezolid (20.9%), and of Enterococcus faecium to daptomycin (10.5%) in isolates from intensive care units are a worrying.

Rev Esp Quimioter 2016; 29(Suppl. 1):6-9 [pdf]

Rev Esp Quimioter 2016, 29(5):239-243

The clinical microbiologist before the taxonomic changes in the genus Clostridium                     

JOSÉ ELÍAS GARCÍA-SÁNCHEZ, ENRIQUE GARCÍA-SÁNCHEZ, MARÍA GARCÍA-MORO          

The various species included in the genus Clostridium are very heterogeneous, both from a phenotypic and a phylogenetic point of view. The advances in polyphasic taxonomy, particularly in phylogeny, are allowing to resolve this dysfunction reclassifying several species in other genres, although there is still work to be done. Changes in generic denominations are quite normal in taxonomy, but can turn into a problem when they affect species with strong clinical impact and that have been recognised for a long time, as in the case of some traditional Clostridium species. After knowing these changes clinical microbiologists, in whose work taxonomy is an essential tool, should evaluate what matters most, if the communication with other health professionals or the phylogeny, and think about the possibility of combining both things. This paper reviews some of the taxonomic changes that have took place in well-known Clostridium species that can be clinically interesting and evaluates, as far as possible, their significance in the scientific and medical communication.

Rev Esp Quimioter 2016; 29(5):239-243 [pdf]

Rev Esp Quimioter 2017; 30(1):62-78

Diagnosis and treatment of imported eosinophilia in travellers and immigrants: Recommendations of the Spanish Society of Tropical Medicine and International Health (SEMTSI)                    

JOAQUÍN SALAS-CORONAS, GERMÁN RAMÍREZ-OLIVENCIA, JOSÉ LUIS PÉREZ-ARELLANO, MONCEF BELHASSEN-GARCÍA, CRISTINA CARRANZA-RODRÍGUEZ, MAGDALENA GARCÍA-RODRÍGUEZ, JUDIT VILLAR-GARCIA, BEGOÑA TREVIÑO-MARURI, NURIA SERRE-DELCOR, ROGELIO LÓPEZ-VÉLEZ, FRANCESCA NORMAN, JOAN GÓMEZ-JUNYENT, MANUEL JESÚS SORIANO-PÉREZ, GERARDO ROJO-MARCOS, ESPERANZA RODRÍGUEZ DE LAS PARRAS, MARÍA DEL MAR LAGO-NÚÑEZ, ANTONIO MURO, JOSÉ MUÑOZ           

According to published data, prevalence of imported eosinophilia among travellers and immigrants is set between 8% and 28.5%. Etiological diagnosis is often troublesome, and depending on the depth of the study and on the population analyzed, a parasitic cause is identified in 17% to 75.9% of the individuals. Among the difficulties encountered to compare studies are the heterogeneity of the studied populations, the type of data collection (prospective/retrospective) and different diagnostic protocols. In this document the recommendations of the expert group of the Spanish Society of Tropical Medicine and International Health (SEMTSI) for the diagnosis and treatment of imported eosinophilia are detailed.

Rev Esp Quimioter 2017; 30(1):62-78  [pdf]